First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Jeffrey Glazer expressed his enthusiasm about the collaboration, saying, "This exclusive licensing agreement with Georgetown University marks a pivotal moment for Aubex Therapeutics. ATX100 has ...

The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

This flexible solution automates manual processes, supporting diverse manufacturing tasks. It's programmable for various processes, including optimized cell culture expansion and streamlining ...

Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.

Large and small drugmakers are vying for a piece of what analysts view as one of the biggest market opportunities in the pharma industry's history. Here’s what’s coming next.

The new policy aims to ensure important diagnostics remain available to patients, but some experts caution the increased regulatory burden could slow access to testing.

Increasing the production capacity for Zepbound and Mounjaro is “the most ambitious expansion plan in our company’s history,” said CEO David Ricks.

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

The funds will help the cancer-focused startup Enlaza bring several candidates toward human testing in the next few years, its CEO said.

DDReg is thrilled to announce its participation as exhibitors at BIO and DIA Global 2024 to provide biotech and ...